S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:RNA

Avidity Biosciences - RNA Stock Forecast, Price & News

$24.24
+0.31 (+1.30%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.55
$24.70
50-Day Range
$10.06
$24.24
52-Week Range
$9.83
$24.70
Volume
775,855 shs
Average Volume
808,175 shs
Market Capitalization
$1.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60

Avidity Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
84.0% Upside
$44.60 Price Target
Short Interest
Bearish
14.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.28mentions of Avidity Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$220,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.30) to ($3.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

719th out of 1,030 stocks

Pharmaceutical Preparations Industry

364th out of 502 stocks

RNA stock logo

About Avidity Biosciences (NASDAQ:RNA) Stock

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

Avidity Biosciences (NASDAQ:RNA) Shares Down 5.4%
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Expert Ratings for Avidity Biosciences
Avidity's stock rallies 39% on new RNA data
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.60
High Stock Price Forecast
$71.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+84.0%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-118,010,000.00
Net Margins
-1,950.91%
Pretax Margin
-1,950.91%

Debt

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$8.13 per share

Miscellaneous

Free Float
50,868,000
Market Cap
$1.32 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 53)
    Ph.D., Co-Founder & Chairman
    Comp: $65k
  • Ms. Sarah Boyce (Age 50)
    Pres, CEO & Director
    Comp: $1M
  • Mr. Michael F. MacLean (Age 56)
    Chief Financial & Bus. Officer
    Comp: $650.38k
  • Dr. W. Michael Flanagan Ph.D. (Age 60)
    Chief Technical Officer
    Comp: $1M
  • Dr. Arthur A. Levin Ph.D. (Age 68)
    Chief Scientific Officer
    Comp: $662.86k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D. (Age 72)
    Scientific Founder & Member of Scientific Advisory Board
  • Ms. Kathleen Gallagher
    Sr. VP of Corp. Communications & Investor Relations
  • Dr. John W. Wallen III (Age 64)
    VP of Intellectual Property, Gen. Counsel & Sec.
  • Ms. Teresa McCarthy
    Chief HR Officer













RNA Stock - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month price objectives for Avidity Biosciences' shares. Their RNA share price forecasts range from $27.00 to $71.00. On average, they anticipate the company's stock price to reach $44.60 in the next year. This suggests a possible upside of 84.0% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2023?

Avidity Biosciences' stock was trading at $22.19 on January 1st, 2023. Since then, RNA shares have increased by 9.2% and is now trading at $24.24.
View the best growth stocks for 2023 here
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) announced its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.15. The biotechnology company had revenue of $2.48 million for the quarter, compared to the consensus estimate of $2.39 million. Avidity Biosciences had a negative net margin of 1,950.91% and a negative trailing twelve-month return on equity of 42.97%.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Aaron Wealth Advisors LLC (0.25%), New York State Common Retirement Fund (0.16%), Simplex Trading LLC (0.00%), Harbor Capital Advisors Inc. (0.08%), AtonRa Partners (0.05%) and DekaBank Deutsche Girozentrale (0.04%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce.
View institutional ownership trends
.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $24.24.

How much money does Avidity Biosciences make?

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $1.32 billion and generates $9.33 million in revenue each year. The biotechnology company earns $-118,010,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis.

How many employees does Avidity Biosciences have?

The company employs 125 workers across the globe.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com.

This page (NASDAQ:RNA) was last updated on 2/3/2023 by MarketBeat.com Staff